New drug mimics IVIg to fight low platelet disorder

NCT ID NCT07095127

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called NVG-2089 in 30 adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The drug is designed to work like IVIg, calming the immune system. Researchers will check for side effects and see if it raises platelet counts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

NVG-2089

What this could lead to

If successful, this could provide a new treatment option for people with immune thrombocytopenia, helping to raise platelet counts and reduce bleeding risk.

What could go wrong

This is an early Phase 2 trial with only 30 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve platelet counts significantly.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA (ITP) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Purpura, Thrombocytopenic, Idiopathic thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • East Carolina University

    RECRUITING

    Greenville, North Carolina, 27834, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••